Theravance Biopharma Inc (NASDAQ:TBPH) Sees Large Drop in Short Interest

Theravance Biopharma Inc (NASDAQ:TBPH) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 4,365,500 shares, a decrease of 16.1% from the July 31st total of 5,202,500 shares. Approximately 10.2% of the shares of the company are sold short. Based on an average daily volume of 287,400 shares, the days-to-cover ratio is currently 15.2 days.

TBPH has been the topic of several research reports. BidaskClub upgraded shares of Theravance Biopharma from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Theravance Biopharma in a research report on Monday. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. Theravance Biopharma has an average rating of “Buy” and an average target price of $44.25.

TBPH stock traded down $0.05 during mid-day trading on Friday, reaching $23.62. 317 shares of the company traded hands, compared to its average volume of 196,620. The company has a market capitalization of $1.35 billion, a P/E ratio of -5.89 and a beta of 1.72. Theravance Biopharma has a 52-week low of $15.18 and a 52-week high of $35.48. The company has a fifty day moving average price of $20.88 and a 200-day moving average price of $20.65.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.50. The business had revenue of $26.15 million during the quarter, compared to analyst estimates of $13.92 million. Theravance Biopharma had a negative return on equity of 2,631.15% and a negative net margin of 369.67%. Analysts expect that Theravance Biopharma will post -4.28 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Opti Capital Management LP bought a new position in shares of Theravance Biopharma in the 2nd quarter worth $1,303,000. DekaBank Deutsche Girozentrale boosted its position in shares of Theravance Biopharma by 21.9% during the first quarter. DekaBank Deutsche Girozentrale now owns 11,700 shares of the biopharmaceutical company’s stock worth $337,000 after buying an additional 2,100 shares during the period. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 0.6% in the second quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock valued at $9,041,000 after acquiring an additional 3,547 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Theravance Biopharma in the first quarter valued at $156,000. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Theravance Biopharma by 882.7% in the first quarter. BNP Paribas Arbitrage SA now owns 9,965 shares of the biopharmaceutical company’s stock valued at $226,000 after acquiring an additional 8,951 shares in the last quarter. 84.16% of the stock is owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Recommended Story: How is Preferred Stock Different from Common Stock?

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.